Radiation medicine innovations for the new millenium

Journal of the National Medical Association

Volumn 95, Issue 1, 2003, Pages 55-63

  Heron, Dwight E ^b   Godette, Karen D ^b   Wynn, Ray A ^b   Arterbery, Elayne ^b   Streeter, Oscar A ^b   Roach III, Mack ^b   Simpson, Joseph R ^b   Blough, Melissa ^b   Thomas Jr , Charles R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE

Author keywords

Cancer; Innovation; Radiation therapy; Technological advances

Indexed keywords

BEAM THERAPY; BENIGN TUMOR; BRACHYTHERAPY; CANCER RADIOTHERAPY; CONTRAST ENHANCEMENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSURGERY; REVIEW; STEREOTAXIC SURGERY; SURVIVAL; THREE DIMENSIONAL IMAGING; TREATMENT PLANNING; TUMOR VOLUME; COMPUTER ASSISTED RADIOTHERAPY; FEMALE; MALE; METHODOLOGY; NEOPLASM; RADIOTHERAPY;

BRACHYTHERAPY; FEMALE; HUMANS; MALE; NEOPLASMS; RADIOSURGERY; RADIOTHERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL;

EID: 0037265266     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Sterling TD, Knowlton KC, Weinkam JJ, Sterling DM. Dynamic display of radiotherapy plans using computer-produced films. Radiology. 1973;107:689-691.
2. Armstrong J, Burman C, Leibel S, et al. Conformal three dimensional treatment planning may improve the therapeutic ratio of high dose radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 1991;21(suppl):146.
3. Robertson JM, Ten Haken RK, Hazuka MB, et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1079-1085.
4. Marks LB, Spencer DP, Sherouse GW, et al. The role of three dimensional functional lung imaging in radiation treatment planning: the functional dose-volume histogram. Int J Radiat Oncol Biol Phys. 1995;33:65-75.
5. Sandler HM, Hayman JA, Sullivan MA, et al. Results of 3D conformal radiation therapy for patients potentially suitable for radical prostatectomy. Proc Am Soc Clin Oncol. 1998;17:307a.
6. Sandler HM, McLaughlin PW, Ten Haken RK, et al. Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys. 1995;33:797-801.
7. Roach M 3rd, Chin DM, Holland J, Clarke M. A pilot survey of sexual function and quality of life following 3-D conformal radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1996;35:869-874.
8. Eisbruch A, Ship JA, Martel MK, et al. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results. Int J Radiat Oncol Biol Phys. 1996;36:469-480.
9. Martel MK, Sandler HM, Cornblath WT, et al. Dose-volume complication analysis for visual pathway structures of patients with advanced paranasal sinus tumors. Int J Radiat Oncol Biol Phys. 1997;38:273-284.
10. McGinn CJ, Ten Haken RK, Ensminger WD, Walker S, Wang S, Lawrence TS. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol. 1998;16:2246-2252.
11. Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl. 1985;8:S13-19.
12. Lawrence TS, Ten Haken RK, Kessler ML, et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys. 1992;23:781-788.
13. Leksell L. A stereotactic apparatus for intracerebral surgery. Acta Chir Scand. 1949;99:229-233.
14. Leksell L. Stereotaxis and Radiosurgery: An Operative System. Springfield, IL: Thomas; 1971.
15. Salter BJ, Fuss M, Vollmer DG, et al. The TALON removable head frame system for stereotactic radiosurgery/radiotherapy: measurement of the repositioning accuracy. Int J Radiat Oncol Biol Phys. 2001;51:555-562.
16. Mehta MP, Masciopinto J, Rozental J, et al. Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys. 1994;30:541-549.
17. Loeffler JS, Alexander E 3rd, Shea WM, et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol. 1992;10:1379-1385.
18. Sarkaria JN, Mehta MP, Loeffler JS, et al. Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1995;32:931-941.
19. Curran WJ Jr, Scott CB, Weinstein AS, et al. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J Clin Oncol. 1993;11:857-862.
20. Larson DA, Gutin PH, McDermott M, et al. Gamma knife for glioma: selection factors and survival. Int J Radiat Oncol Biol Phys. 1996;36:1045-1053.
21. Auchter RM, Lamond JP, Alexander E, et al. A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastases. Int J Radiat Oncol Biol Phys. 1996;35:27-35.
22. Shu H-KG, Sneed PK, Shiau C-Y, et al. Factors influencing survival after Gamma knife radiosurgery for patients with single and multiple brain metastases. Cancer J Sci Am. 1996;2:335-342.
23. Shu HKG, Sneed PK, Shiau CY, et al. Factors influencing survival after Gamma knife radiosurgery for patients with single and multiple brain metastases. Cancer J Sci Am. 1996;2:335.
24. Shiau CY, Sneed PK, Shu HK, et al. Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. Int J Radiat Oncol Biol Phys. 1997;37:375-383.
25. Kondziolka D, Lunsford LD, Flickinger JC. Controversies in the management of multiple brain metastases: the roles of radiosurgery and radiation therapy. Forum. 2001;11:47-58.
26. Jyothirmayi R, Saran FH, Jalali R, et al. Stereotactic radiotherapy for solitary brain metastases. Clin Oncol. 2001;13:228-234.
27. Kim DG, Chung HT, Gwak HS, Paek SH, Jung HW, Han DH. Gamma knife radiosurgery for brain metastases: prognostic factors for survival and local control. J Neurosurg. 2000;9(Suppl 3):23-29.
28. Flickinger JC, Kondziolka D, Pollock BE, Lunsford LD. Evolution in technique for vestibular schwannoma radiosurgery and effect on outcome. Int J Radiat Oncol Biol Phys. 1996;36:275-280.
29. Foote RL, Coffey RJ, Swanson JW, et al. Stereotactic radiosurgery using the gamma knife for acoustic neuromas. Int J Radiat Oncol Biol Phys. 1995;32:1153-1160.
30. Coffey RJ, Nichols DA, Shaw EG. Stereotactic radiosurgical treatment of cerebral arteriovenous malformations. Gamma Unit Radiosurgery Study Group. Mayo Clin Proc. 1995;70:214-222.
31. Flickinger JC, Kondziolka D, Pollock BE, et al. Complications from arteriovenous malformation radiosurgery: multivariate analysis and risk modeling. Int J Radiat Oncol Biol Phys. 1997;38:485-490.
32. Wilder RB. Treatment of arteriovenous malformations with stereotactic radiosurgery: A review. Radiat Oncol Invest. 1994;2:57-65.
33. Chang JH, Chang JW, Park YG, Chung SS. Factors related to complete occlusion of arteriovenous malformations after gamma knife radiosurgery. J Neurosurg. 2000;93(Suppl 3):96-101.
34. Flickinger JC, Kondziolka D, Lunsford LD. Radiosurgery for benign lesions. Semin Radiat Oncol. 1995;5:220-224.
35. Jankovic J, Cardoso F, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995;37:680-686.
36. Duma CM, Jacques DB, Kopyov OV, Mark RJ, Copcutt B, Farokhi HK. Gamma knife radiosurgery for thalamotomy in parkinsonian tremor: a five-year experience. J Neurosurg. 1998;88:1044-1049.
37. Young RF, Shumway-Cook A, Vermeulen SS. et al. Gamma knife radiosurgery as a lesioning technique in movement disorder surgery. J Neurosurg. 1998;89:183-193.
38. Kuppersmith RB, Greco SC, Teh BS, et al. Intensity-modulated radiotherapy: first results with this new technology on neoplasms of the head and neck. Ear Nose Throat J. 1999;78:238, 241-246.
39. Chao KS, Low DA, Perez CA, Purdy JA. Intensity-modulated radiation therapy in head and neck cancers. The Mallinckrodt experience. Int J Cancer. 2000;90:92-103.
40. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Rad Oncol Biol Phys. 2001;50:695-704.
41. Chao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol. 2001;50:907-916.
42. Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000;55:241-249.
43. Ma L, Yu CX, Earl M, et al. Optimized intensity-modulated arc therapy for prostate cancer treatment. Int J Cancer. 2001;96:379-384.
44. Martinez AA, Yan D, Lockman D, et al. Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer. Int J Radiat Oncol Biol Phys. 2001;50:1226-1234.
45. Shu HK, Lee TT, Vigneauly E, et al. Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer. Urology. 2001;57:102-107.
46. Teh BS, Mai WY, Uhl BM, et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis. Int J Radiat Oncol Biol Phys. 2001;49:705-712.
47. Nutting CM, Convery DJ, Cosgrove VP, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:649-656.
48. De Meerleer GO, Vakaet LA, De Gersem WR, et al. Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys. 2000;47:639-648.
49. Landry J. Intensity modulated radiation therapy employing the volume at risk approach to minimize small bowel and renal toxicity when treating patients with locally advanced pancreatic carcinoma (Abstract). Annual meeting of American Society for Therapeutic Oncology, 2001.
50. Landry JC, Yang GY, Ting JY, et al. Treatment of pancreatic cancer tumor with intensity modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Medical Dosimetry. 2002;121-129.
51. Garton GR, Gunderson LL, Nagorney DH, et al. High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer. Intl J Rad Oncol Biol Phys. 1993;27:1153-1157.
52. RTOG 0012-Randomized phase II trial of preoperative combined modality chemoradiation for distal rectal cancer. Activated 2/1/01.
53. Zelefsky MJ, Hollister T, Raben A, et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent 1-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47:1261-1266.
54. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the five-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999;17:517-522.
55. Wallner K, Roy J, Harrison L. Tumor contol and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 1996;14:449-453.
56. Grimm P. Prostate Brachytherapy Clinical Refresher Course, Radiologic Society of North America, 1997.
57. Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology. 2001;58:393-397.
58. Wallner K. Improved outcomes with radiation for prostate cancer. Hematol Oncol Clin of North Am. 2001;15:359-375.
59. Streeter OE, Goldson AL, Chevallier C, Nibhanupudy JR. High dose rate 60Co remote afterloading irradiation in cancer of the cervix in Haiti, 1977-1984. Int J Radiat Oncol Biol Phys. 1988;14:1159-1163.
60. Chatani M, Matayoshi Y, Masaki N, et al. Long term follow-up results of high-dose rate remote afterloading intracavitary radiation therapy for carcinoma of the uterine cervix. Strahlenther Onkol. 1994;170:269-276.
61. Petereit DG, Sarkaria JN, Potter DM, Schink JC. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence - the University of Wisconsin experience. Int J Rad Oncol Biol Phys. 1999;45:1267-1274.
62. Chatani M, Matayoshi Y, Masaki N, et al. A prospective randomized study concerning the point A dose in high-dose rate intracavitary therapy for carcinoma of the uterine cervix. The final results. Strahlenther Onkol. 1994;170:636-642.
63. Gollins SW, Burt PA, Barber PV, Stout R. High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients. Radiother Oncol. 1994;33:31-40.
64. Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy. Cancer. 1974; 34:1278-1292.
65. Kuehne J, Kleisli T, Biernacki P, et al. The use of high-dose-rate brachytherapy in the management of locally recurrent rectal cancer. Dis. Colon Rectum. (Accepted for publication, with revisions, submitted April 10, 2002).
66. Speight JL, Luxton G, Jozsef G, et al. Sequential chemoradiation and intraluminal brachytherapy for the treatment of adeno and squamous cell carcinoma of the esophagus: A USC/Norris Pilot Trial. Radiology. 1997;205(P):397.
67. Speight JL, Streeter Jr OE, Chawla S, et al. High dose rate brachytherapy for the treatment of soft tissue sarcoma of the extremity. Radiother and Oncol. 1996;39(suppl):S18.
68. Mate TP, Gottesman JE, Hatton J, Gribble M, Van Hollebeke L. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiation Oncology Biol Phys. 1998;41:525-533.
69. Martinez AA, Pataki I, Edmundson G, et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys. 2001;49:61-69.
70. Orton CG. High-dose-rate brachytherapy may be radiobiologically superior to low-dose rate due to slow repair of late-responding normal tissue cells. Int J Radiat Oncol Biol Phys. 2001;49:183-189.
71. Bolton J, Kuske R, Sardi A, et al. Radiation therapy (RT) in early stage breast cancer: can brachytherapy replace external beam whole breast radiation therapy (WhBRT) in patients treated with breast conserving therapy (BCT) - results of a pilot study. Proc Annual Meet Am Soc Clin Oncol. 1993;12:87.
72. Kuske RR, Bolton JS, Fuhrman G, et al. Wide volume brachytherapy alone for select breast cancers: The ten-year experience of the Ochsner Clinic. Int J Radiat Oncol Biol Phys. 2000;48:3(suppl):296.
73. Vicini FA, Baglan KL, Kestin LL, et al. Accelerated treatment of breast cancer. J Clin Oncol. 2001;19:1993-2001.
74. Bittl JA. Advances in coronary angioplasty. N Engl J Med. 1996;335:1290-1302.
75. Mak KH, Topol EJ. Clinical trials to prevent restenosis after percutaneous coronary revascularization. Ann NY Acad Sci. 1997;811:255-284.
76. Serrys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
77. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement in balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501.
78. Erble R, Haude M, Hopp HW, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med. 1998;339:1672-1678.
79. Lui MW, Roubin GS, King SB 3rd. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation. 1989;79:1374-1387.
80. Condado JA, Waksman R, Gurdiel O, et al. Long-term angiographc and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans. Circulation. 1997;96:727-732.
81. Teirstein PS, Massullo V, Jani S, et al. Three-Year clinical and angiographic follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 2000;101:360-365.
82. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001;344:250-256.
83. Verin V, Popowski Y, de Bruyne B, et al. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. N Engl J Med 2001;344:243-249.